Legal Battle Erupts Over Residency Application Software Competition
Thalamus, a graduate medical education software company, has filed a lawsuit against competitor Liaison International and ob/gyn leader Maya Hammoud, alleging anticompetitive conduct and breach of a non-disclosure agreement. The suit follows the departure of several specialties from the AAMC's ERAS platform to Liaison's ResidencyCAS, which has raised concerns about ERAS's revenue. Thalamus claims the defendants coordinated to unfairly compete in the residency application market.
Thalamus maintained a close alliance with the Association of American Medical Colleges, which later acquired an equity stake in the company. The departure of obstetrics and gynecology, followed by emergency medicine, to Liaison's platform caused significant worry within the AAMC about losing its primary income stream.
Hammoud served as lead investigator on a joint pilot project with Thalamus, the American Medical Association, and APGO, receiving full product access under strict confidentiality terms. A separate non-disclosure agreement between Thalamus and Liaison occurred in late 2022, yet the specialty switch happened shortly after. A distinct antitrust case against the AAMC exists, illustrating Thalamus's varying legal roles.
This litigation could reshape the competitive dynamics of residency application software. If Thalamus succeeds, it may discourage other firms from entering the market, potentially limiting innovation and raising costs for programs and applicants. Conversely, a Liaison victory may accelerate the migration away from ERAS, altering application workflows and financial pressures on medical schools. The outcome could also influence how the AAMC manages its revenue dependencies, affecting future application fees and system stability.